Industry landscapes
The companies, capital and talent shaping healthtech in Chennai. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
Recently founded means a recorded 2023–2026 founding year and no recorded parent, acquirer or public-company status. These companies are not labelled startups without that separate classification.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
26 of 393 tracked companies have open roles.
58 of 393 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 82 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 79.6% of disclosed capital, while 85.2% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $1.96M | 29 | 4 |
| 2017 | $16.98M | 28 | 11 |
| 2018 | $35.67M | 17 | 5 |
| 2019 | $335.57K | 21 | 3 |
| 2020 | $779.58K | 29 | 5 |
| 2021 | $1.35M | 37 | 7 |
| 2022 | $85.55M | 25 | 16 |
| 2023 | $4.59M | 24 | 8 |
| 2024 | $2.11M | 12 | 5 |
| 2025 | $14.22M | 6 | 5 |
Share of all disclosed company funding.
101 recorded rounds since 2016
Recorded participation in healthtech company rounds since 2016.
Backed by HealthQuad.
Backed by Orbimed.
Backed by Eight Roads Ventures and Fidelity Investments and others.
Backed by Orbimed.
Backed by Daun Penh Cambodia Group and Sistema Asia Capital and others.
Backed by True North.
Backed by Sistema Asia Capital and Tanncam Investment.
Backed by Norwest.
Backed by EPlanet Capital and Headlands Capital and others.
Backed by MAPE.
Backed by Accel and Chiratae Ventures and others.
Annual accounts for reporting companies linked to this landscape, on like-for-like currency and reporting bases.
Display conversions use the dated reference rates above. Where a verified rate is unavailable, figures retain their source currency. Each reporting cohort keeps its currency and accounting basis separate.
FY2025 · annual statements grouped by reported fiscal year; exact entity periods remain on preview rows · 112 reporting entities from 152 eligible matches.
Sum of reporting-entity revenue; not Chennai market sales.
Combined result for the same cohort.
Combined net income ÷ combined revenue.
The middle covered reporting entity.
46 of 112 covered entities.
Share of covered revenue from the five largest entities.
Reported cohort totals by year; coverage is stated for every period.
Bar height shows revenue. Changes in coverage can affect totals.
FY2025 · 112 reporting entities
Up to eight fixed company previews show financial amounts. Search and sort the wider company list, then continue in Radar.
| Company / reporting entity | Revenue | Net profit / loss | Net margin | Revenue growth | Total assets |
|---|---|---|---|---|---|
| Trivitron ↗U85110TN1998PTC040515 | ₹227.6 crore | ₹1.4 crore | +0.6% | — | ₹453.7 crore |
| Avana Medical ↗U74999TN2009PTC071443 | ₹212.5 crore | ₹23.1 crore | +10.9% | — | ₹171.7 crore |
| Spectra Medicals ↗U51397TN2011PTC082151 | ₹177.8 crore | ₹19.1 crore | +10.7% | — | ₹113.8 crore |
| Athenese-Dx ↗U85100TN2012PTC084632 | ₹85.2 crore | ₹5.9 crore | +6.9% | — | ₹50.5 crore |
| Phoenix Medical Systems ↗U85110TN1987PTC014743 | ₹73.5 crore | ₹7.6 crore | +10.4% | — | ₹147.9 crore |
| Netmeds ↗U51505MH2010PLC447670 | ₹43.7 crore | ₹5.8 crore | +13.3% | — | ₹55.9 crore |
| S2M Health ↗U72900TN2016PTC104260 | ₹39.6 crore | ₹3.1 crore | +7.9% | — | ₹41.0 crore |
| Kriya ↗U29268TN2006PTC061110 | ₹20.7 crore | ₹-18.1 crore | -87.2% | — | ₹102.7 crore |
Explore full company accounts and filings.
Choose “View accounts” to inspect an available company preview.
Each pair uses the same year, currency and reporting basis. Cohort overlap is disclosed.
| Industry | Covered / eligible | Revenue total | Median revenue | Net profit / loss | Aggregate margin | Profitable share | Overlap |
|---|
Available-account cohorts are not estimates of whole industries. Overlapping entities can occur in more than one cohort; do not add cohort totals.
Filed annual accounts for exact designated national identifiers. Every aggregate and peer pair uses one fiscal year, source currency and reporting basis; periods, coverage and overlap are explicit; 2026 partials are excluded.
The same up to eight reporting entities remain open across years, filters and sorts. Other company figures are available in Radar.
Source currencies and accounting bases stay separate. Missing accounts are excluded rather than treated as zero. Exact reporting periods appear on company previews. Annual totals can change with coverage and do not measure growth of a fixed company cohort.
How the Chennai companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
48 of these companies (12.2%) publish at least one Android app — 96 apps in all, carrying 26.1M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| Netmeds - India Ki PharmacyNetmeds | 25.2M | 4.4 | Medical |
| MyMedicalShop Online PharmacyMyMedicalShop | 178.3K | — | Shopping |
| Medugo-Health Vitals On the GoMedugo | 124.7K | — | Health & Fitness |
| MrMed Super-Specialty PharmacyMrMed | 104.5K | — | Medical |
| Mind&Mom : Fertility|PregnancyMind&Mom | 98.9K | — | Health & Fitness |
| My+HealthHelyxon | 60.1K | — | Health & Fitness |
| Diahome For PatientDiaHome | 34.3K | — | Health & Fitness |
| Treat at Home: Doctor OnDemandTreat At Home | 34.2K | — | Medical |
| KauveryMedsKauveryMeds | 32K | — | Medical |
| OneGlanceOneGlance | 26.4K | — | Health & Fitness |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2023Q3–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Healthcare Booking Platforms | 28 | 25.7M | Netmeds - India Ki Pharmacy 25.2M | |
| Disease Self Management | 12 | 247.5K | Medugo-Health Vitals On the Go 124.7K | |
| Healthcare It | 52 | 168.3K | My+Health 60.1K | |
| Wearable Technology | 2 | 124.9K | AlcoChange Trial 249 | |
| Clinical Labs It | 4 | 22.3K | MocDoc 16K | |
| Fitness & Wellness Tech | 2 | 21K | Anyo for wellness 12.4K | |
| Pharmacy It | 3 | 19.6K | MocDoc Patient Connect 3.6K | |
| Diversified Medical Devices | 2 | 1K | Trivitron CONNECT 1K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 61 of 96 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
20 companies hiring · $137.28M disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Healthcare entrepreneur GSK Velu is accelerating strategic investments and R&D in new-age technologies for his group companies, setting the ground for a public listing of Neuberg Diagnostics, Maxivision Super Speciality Eye Hospitals, and Trivitron Healthcare.
Allica bank is poised to significantly expand its lending capacity for small businesses with the acquisition of London-based fintech Kriya
HCTI acquired Niyama and Ezovion, two software groups with complementary strengths in automation and digital patient management.
IITM incubated startup Plenome, raised 6.5 cr rupees in seed funding to develop Blockchain tech, for safe data transfers and to stretch into global market sectors like, healthcare and voting.
Tvaster Genkalp has raised $1.25 million in a pre‑Series A funding round led by Ideaspring Capital, which was joined by existing investors including Invigo Softwares and liver transplant surgeon Mohamed Rela.
MrMed has expanded its physical presence with the establishment of on-ground operations in Guwahati, alongside its existing presence in Chennai, Delhi and Bengaluru.
Warburg Pincus’ acquisition of a controlling stake in Appasamy Associates, India’s largest ophthalmic equipment and intraocular lens manufacturer, in April.
Top 6 categories among 13 recorded events in the 24-month window.
1 companies with recorded IPO activity
IPO1 reports
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| allica bank→Kriya ↗ | Announced | 2025-10-27 | Not stated in snapshot |
| healthcare triangle→Ezovion ↗ | Completed | 2025-10-10 | Not stated in snapshot |
| warburg pincus→Appasamy Associates ↗ | Announced | 2025-09-11 | $300.0M |
| reliance→Netmeds ↗ | 2025-07-21 | Not stated in snapshot | |
| Bharath Home Medicare→strata | Completed | 2023-11-10 | Not stated in snapshot |
| Trivitron→Bome Sanayi Urunleri Dis Tic Ltd Sti | Announced | 2023-07-11 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
563 postings in the preceding 12 months. The full 665-posting snapshot covers 303 employers.
4 tracked postings mention remote work.
292 postings specify a level.
Top skills across 665 tracked postings in the available jobs snapshot.
Median across 175 postings with pay data, expressed in USD.
| Company | Employees |
|---|---|
| S2M Health ↗ | 1,100 |
| Techindia ↗ | 472 |
| Trivitron ↗ | 393 |
| Athenese-Dx ↗ | 331 |
| Phoenix Medical Systems ↗ | 175 |
| nice Neotech Medical Systems ↗ | 164 |
| Spectra Medicals ↗ | 137 |
| Avana Medical ↗ | 84 |
291 founders and chief executives across 221 companies.
BITS Pilani BPharm 1988, Loyola Institute Of Business Administration MBA
Ex-Shasun Biotechnology, Pfizer, GE HealthCare. Anna University BTech 2000, The University of Texas at Dallas MS 2002
Bharat Dynamics, ex-Perfint Engineering Services, Cognizant Technology Solutions.
Ex-Founder Tungstn, Posdol Foods, Chudar · Madras University BE 2015, Stoa MBA 2022
Ex-Ford Motor Company. Barathiar University BTech 1990, Oakland University 1995
Ex-Founder Reverease. National Institute of Technology Tiruchirappalli BE 1986
Ex-Levim biotech · Ex-SRM IST Chennai BTech 2014, Vellore Institute of Technology MTech 2021
bob e procure solutions pvt ltd, Insta Health Solutions Pvt Ltd, Wanbury Ltd, Madurai Kamaraj University
Co-Founder 'Coz Coffee, ex-Mitra WHL, Madmonkey Motomotives.
Co-Founder NeuroTechX. SASTRA Deemed University 2019
Tricept Life Sciences, ex-Remedi Speciality Medicines. Manipal Academy of Higher Education BSc 2009, Drexel University BS 2012
Ex-Allergan, Ranbaxy · Vivekananda College BSc 1990, Manipal Academy of Higher Education MBA 2005
32 profiles with education records.
5 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
39,405 articles in the measured 12-month window.
Healthtech coverage tagged Chennai · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 4,527 |
| 2021Q3 | 4,277 |
| 2021Q4 | 3,775 |
| 2022Q1 | 4,335 |
| 2022Q2 | 5,157 |
| 2022Q3 | 6,275 |
| 2022Q4 | 6,341 |
| 2023Q1 | 6,755 |
| 2023Q2 | 7,224 |
| 2023Q3 | 7,377 |
| 2023Q4 | 7,754 |
| 2024Q1 | 6,517 |
| 2024Q2 | 6,539 |
| 2024Q3 | 9,245 |
| 2024Q4 | 7,812 |
| 2025Q1 | 8,463 |
| 2025Q2 | 5,928 |
| 2025Q3 | 7,247 |
| 2025Q4 | 7,658 |
| 2026Q1 | 16,171 |
Article volume measures coverage, not market sales.
12 recorded company events across 5 companies; percentages use that event total.
Healthtech coverage tagged Chennai · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
India comparison coverage
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| tariff negotiations | 11,620 | 5,680 | 105% |
| bilateral trade | 4,610 | 2,437 | 89% |
| trade dispute mechanisms | 4,511 | 2,203 | 105% |
| trade barrier reduction | 4,496 | 2,440 | 84% |
| trade facilitation commitments | 4,327 | 2,201 | 97% |
| countries | 4,193 | 1,860 | 125% |
| free trade deals | 4,078 | 2,429 | 68% |
| multilateral diplomacy | 3,918 | 2,723 | 44% |
| diplomatic strategies | 3,816 | 2,350 | 62% |
| bilateral trade imbalance | 3,281 | 2,044 | 61% |
| odi cricket | 6,036 | 9,660 | -38% |
| limited overs cricket | 5,777 | 9,308 | -38% |
| odi tactics | 5,628 | 8,746 | -36% |
| odi series | 5,256 | 8,324 | -37% |
| odi tournaments | 5,032 | 8,067 | -38% |
India comparison coverage
territories, disputed islands, test cricket
44.3% critical · 27.2% positivepre-ipo valuation, ipo prospectus, ipo pricing
49.3% critical · 46.7% positivegdp growth rate, economic output growth, economic growth statistics
46.9% critical · 50.7% positiveHealthtech coverage tagged Chennai. Topic labels describe recorded classifications and can include broad context.
3,029 papers in the recorded india scope.
Tone counts: 2,771 positive · 35 neutral · 223 negative.
Landmark: Barriers and facilitators to utilizing digital health technologies by healthcare professionals
Landmark: Digital mental health apps and the therapeutic alliance: initial review
Landmark: Feature selection and classification systems for chronic disease prediction: A review
Common problems researchers identify · 0123.6% of this theme group
Researchers highlight rising drug resistance and limitations of current medical devices in treating infectious diseases.
Disease (84) · Human health (29) · Antibiotic resistance (37) · Medical device (35)
Leishmaniasis: A multifaceted approach to diagnosis, maladies, drug repurposing and way forward
Multitargeting: An Alternative Approach to Tackle Multidrug Resistancein Tuberculosis
| Year | Share index |
|---|---|
| 2022 | 1311.9 |
| 2023 | 1170.0 |
| 2024 | 1054.1 |
| 2025 | 1320.5 |
Common problems researchers identify · 0221.7% of this theme group
Papers point to barriers and uneven adoption of digital tools in public health and clinical care.
Digital health (175) · Health care (224) · Public health (93) · Health administration (49)
The intersection of technology and mental health: enhancing access and care
Digital Healthcare and Patient Transformation: Review Research and Future Agenda
| Year | Share index |
|---|---|
| 2022 | 449.4 |
| 2023 | 435.7 |
| 2024 | 441.9 |
| 2025 | 764.8 |
Common problems researchers identify · 0313.1% of this theme group
Studies discuss hurdles in applying genomics‑driven, personalized therapies for cancer and ocular disorders.
Precision medicine (227) · Personalized medicine (137) · Cancer (39) · Genomics (22)
Advancing precision medicines for ocular disorders: Diagnostic genomics to tailored therapies
Precision medicine in cancer treatment: Revolutionizing care through proteomics, genomics, and personalized therapies
| Year | Share index |
|---|---|
| 2022 | 764.3 |
| 2023 | 1049.9 |
| 2024 | 798.6 |
| 2025 | 777.4 |
Common problems researchers identify · 0411.7% of this theme group
Authors flag difficulties in embedding AI within healthcare workflows and managing massive data streams.
Health care (131) · Wearable computer (36) · Big data (33) · Applications of artificial intelligence (24)
Artificial Intelligence in Healthcare: Transforming the Future of Medicine
Artificial intelligence and machine learning in healthcare: a comprehensive review
| Year | Share index |
|---|---|
| 2022 | 43.0 |
| 2023 | 45.3 |
| 2024 | 47.8 |
| 2025 | 86.2 |
Common problems researchers identify · 0510.9% of this theme group
Research identifies obstacles in translating natural‑product leads into viable pharmaceutical candidates.
Drug discovery (213) · Drug (105) · Natural product (37) · Drug development (57)
Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective
Drug Discovery and Development Processes
| Year | Share index |
|---|---|
| 2022 | 154.6 |
| 2023 | 159.2 |
| 2024 | 166.2 |
| 2025 | 206.1 |
Common problems researchers identify · 0610.0% of this theme group
Works emphasize technical, regulatory, and acceptance issues limiting remote care expansion.
Telemedicine (193) · Health care (120) · Telehealth (46) · Medical emergency (22)
Telemedicine for healthcare: Capabilities, features, barriers, and applications
Exploring the potential of telemedicine for improved primary healthcare in India: a comprehensive review
| Year | Share index |
|---|---|
| 2022 | 215.3 |
| 2023 | 197.2 |
| 2024 | 209.5 |
| 2025 | 199.0 |
Common problems researchers identify · 078.9% of this theme group
Papers note the rapid surge in telemedicine use during COVID‑19 and the resulting system stresses.
Pandemic (159) · Coronavirus disease 2019 (124) · Telemedicine (110) · 2019-20 coronavirus outbreak (21)
Telehealth and the COVID-19 Pandemic: International Perspectives and a Health Systems Framework for Telehealth Implementation to Support Cri
Comprehending Telemedicine: An Online Survey amidst COVID-19 Pandemic
| Year | Share index |
|---|---|
| 2022 | 548.5 |
| 2023 | 379.1 |
| 2024 | 244.3 |
| 2025 | 190.4 |
Cautions · 0122.9% of this theme group
Caution is urged over limited evidence for genotype‑guided drug selection in oncology.
Pharmacogenomics (12) · Drug (21) · Precision medicine (16) · Cancer (10)
Targeted drug monitoring in oncology for personalized treatment with use of next generation analytics
INVESTIGATIONAL THERAPIES AND TARGETED APPROACHES IN METAPLASTIC BREAST CANCER: A SYSTEMATIC REVIEW OF EMERGING PHARMACOLOGICAL STRATEGIES
| Year | Share index |
|---|---|
| 2022 | 141.0 |
| 2023 | 147.0 |
| 2024 | 157.4 |
| 2025 | 213.9 |
Cautions · 0220.0% of this theme group
Authors warn about over‑reliance on AI without robust validation for patient assessment.
Applications of artificial intelligence (20) · Big data (15) · Precision medicine (26) · Health care (42)
Advancements in the treatment of autoimmune diseases: Integrating artificial intelligence for personalized medicine
Artificial intelligence (AI): using ai to assist in patient assessment, diagnostics, and clinical decision-making
| Year | Share index |
|---|---|
| 2022 | 27.5 |
| 2023 | 30.3 |
| 2024 | 35.4 |
| 2025 | 89.2 |
Cautions · 0314.5% of this theme group
Studies question whether remote consultations match in‑person outcomes for specific patient groups.
Telemedicine (54) · Health care (38) · Telerehabilitation (8) · Medical emergency (8)
Telemedicine in Geriatric Psychiatry: Relevance in India
Telemedicine Versus In-Person Visits in Postoperative Care in Orthopedic Patients: Follow-Up Study From North India
| Year | Share index |
|---|---|
| 2022 | 213.6 |
| 2023 | 195.8 |
| 2024 | 207.4 |
| 2025 | 194.7 |
Cautions · 0412.7% of this theme group
Research highlights mixed results on how digital tools affect overall patient experience and outcomes.
Health care (33) · Digital health (18) · Public health (10) · Health informatics (10)
Utilizing Digital Health Technologies To Improve Patient Experience And Care Quality In Global Healthcare: A Systematic Review
An impact of digital technologies on healthcare and patient outcomes: A review
| Year | Share index |
|---|---|
| 2022 | 453.1 |
| 2023 | 438.9 |
| 2024 | 445.9 |
| 2025 | 773.9 |
Cautions · 0510.5% of this theme group
Cautions focus on the current challenges of AI‑driven pipelines for novel drug discovery.
Drug discovery (35) · Drug (22) · Drug development (11) · Repurposing (8)
Exploring AI-driven approaches to drug discovery and development
The AI-Driven Future of Drug Discovery: Innovations, Applications, and Challenges
| Year | Share index |
|---|---|
| 2022 | 158.5 |
| 2023 | 163.5 |
| 2024 | 171.8 |
| 2025 | 214.7 |
Cautions · 069.9% of this theme group
Papers raise concerns about efficacy, privacy, and dependency associated with mental‑health applications.
Mental health (22) · Psychological intervention (20) · Digital health (20) · Intervention (5)
Digital wellness or digital dependency? a critical examination of mental health apps and their implications
The Role of Technology in Mental Health: Evaluating Digital Interventions for Psychological Well-being
| Year | Share index |
|---|---|
| 2022 | 784.7 |
| 2023 | 800.0 |
| 2024 | 802.5 |
| 2025 | 1143.3 |
Cautions · 079.5% of this theme group
Authors note inconsistent patient satisfaction and adoption patterns during and after the pandemic.
Pandemic (32) · Coronavirus disease 2019 (22) · Telemedicine (25) · Telehealth (13)
A Review of Patient Satisfaction and Experience with Telemedicine: A Virtual Solution During and Beyond COVID-19 Pandemic
International survey of audiologists during the COVID-19 pandemic: use of and attitudes to telehealth
| Year | Share index |
|---|---|
| 2022 | 548.5 |
| 2023 | 379.1 |
| 2024 | 244.3 |
| 2025 | 190.4 |
Opportunities · 0117.9% of this theme group
Opportunities focus on exploiting plant‑derived compounds and antimicrobial peptides for new drug candidates.
Drug discovery (338) · Drug (231) · Combinatorial chemistry (69) · Health benefits (48)
Fungal Endophytes as Efficient Sources of Plant-Derived Bioactive Compounds and Their Prospective Applications in Natural Product Drug Disco
Antimicrobial Peptides: The Production of Novel Peptide-Based Therapeutics in Plant Systems
| Year | Share index |
|---|---|
| 2022 | 164.8 |
| 2023 | 169.5 |
| 2024 | 181.6 |
| 2025 | 220.1 |
Opportunities · 0217.6% of this theme group
Research highlights deep‑learning models and chatbots that can enhance disease detection and personalized care.
Health care (352) · Convolutional neural network (91) · Applications of artificial intelligence (54) · Chatbot (50)
AI in Healthcare: Opportunities and Challenges for Personalized Medicine and Disease Diagnosis
AI-Driven Healthcare Solutions: Utilizing Deep Learning for Predictive Analytics and Personalized Medicine
| Year | Share index |
|---|---|
| 2022 | 36.8 |
| 2023 | 39.0 |
| 2024 | 29.7 |
| 2025 | 47.6 |
Opportunities · 0315.7% of this theme group
Studies explore novel biomarkers and AI to refine targeted cancer therapies and patient stratification.
Precision medicine (419) · Personalized medicine (304) · Cancer (216) · Biomarker (72)
Addressing Challenges and Opportunities in Precision Medicine Using Deep Learning and Personalized Cancer Treatment
Precision and personalized medicine: new way for cancer management
| Year | Share index |
|---|---|
| 2022 | 764.3 |
| 2023 | 1049.9 |
| 2024 | 798.6 |
| 2025 | 777.4 |
Opportunities · 0413.8% of this theme group
Papers present telemedicine as a means to improve access, management, and outcomes for long‑term conditions.
Telemedicine (357) · Health care (305) · Telehealth (103) · Digital health (135)
Optimizing healthcare outcomes and broadening nursing capabilities in digital era: telemedicine transformative impact
Advancing Public Health: A Comprehensive Analysis of Telemedicine in Chronic Disease Management, Access Improvement, and Health Promotion Pr
| Year | Share index |
|---|---|
| 2022 | 65.1 |
| 2023 | 64.6 |
| 2024 | 63.7 |
| 2025 | 106.3 |
Opportunities · 0512.9% of this theme group
Opportunities arise from virtual docking and modeling to accelerate antiviral and other drug discovery.
Virtual screening (376) · Docking (374) · In silico (288) · Computational biology (210)
<i>In Silico</i>molecular docking and dynamic analysis of natural compounds against major non-structural proteins of SARS-COV-2
Insights into novel inhibitors intending HCMV protease a computational molecular modelling investigation for antiviral drug repurposing
| Year | Share index |
|---|---|
| 2022 | 28.9 |
| 2023 | 30.4 |
| 2024 | 28.8 |
| 2025 | 32.8 |
Opportunities · 0611.5% of this theme group
Research emphasizes reusing existing drugs and AI‑assisted synthesis to shorten development timelines.
Drug discovery (513) · Drug (300) · Drug development (107) · Drug repositioning (82)
Drug repurposing: An emerging approach to drug discovery
LEVERAGING ARTIFICIAL INTELLIGENCE IN MEDICINAL CHEMISTRY: ADVANCES IN DRUG SYNTHESIS, DEVELOPMENT AND DESIGN
| Year | Share index |
|---|---|
| 2022 | 158.5 |
| 2023 | 163.5 |
| 2024 | 171.8 |
| 2025 | 214.7 |
Opportunities · 0710.6% of this theme group
Works showcase wearable and IoT platforms for continuous patient tracking and decentralized healthcare delivery.
Remote patient monitoring (196) · Internet of Things (170) · Wearable computer (170) · Health care (244)
IoT-Driven Smart Healthcare Systems for Remote Patient Monitoring and Management
IoT Based Effective Wearable Healthcare Monitoring System For Remote Areas
| Year | Share index |
|---|---|
| 2022 | 40.1 |
| 2023 | 42.4 |
| 2024 | 45.7 |
| 2025 | 72.4 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Promising | 32.3% | 37.1% |
| Breakthrough | 27.0% | 26.4% |
| Problem-identifying | 21.8% | 9.7% |
| Descriptive | 10.8% | 17.4% |
| Cautionary | 5.2% | 4.5% |
| Comparative | 2.4% | 3.8% |
| Critical | 0.6% | 1.1% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceSocial Connectedness, Excessive Screen Time During COVID-19 and Mental Health: A Review of Current Evidence | 370 | 3.08% | 131 (35.4%) | 2.66% |
| Safety & misusePolitical dimensions of misinformation, trust, and vaccine confidence in a digital age | 11 | 0.09% | 7 (63.6%) | 0.17% |
| Hardware, e-waste & supply chainE-wastes Management in AI Context: The Opportunities and Challenges in Educational and Healthcare Waste – <i>A Scientifi | 5 | 0.04% | 1 (20.0%) | 0.01% |
| Energy & datacenter footprintSUSTAINABLE GREEN COMPUTING FOR MEDICAL APPLICATIONS: ADVANCING RESPONSIBLE HEALTHCARE IT | 4 | 0.03% | 3 (75.0%) | 0.01% |
| Carbon & emissions of computeFrom Opaqueness to Transparency: Sustainable AI in Diabetes Prediction | 1 | 0.01% | 0 (0.0%) | 0.0% |
| Labour & data workGIG worker protections: designing a new labour category for the digital economy | 1 | 0.01% | 1 (100.0%) | 0.01% |
| Bias & fairnessA Comprehensive Review of Bias and Fairness in Artificial Intelligence for Oral Cancer Detection | 1 | 0.01% | 1 (100.0%) | 0.06% |
| Concentration of compute powerRole of Artificial Intelligence, Big Tech and Machine Learning in Accelerating Biologics Development and Clinical Trials | 1 | 0.01% | 0 (0.0%) | 0.01% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: India. This may be broader than the company geography.
Published patent filings in the recorded source window.
Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 5 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗